You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)

Article metrics

Article menu

Download PDFPDF

XML
Research Article
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)

 

Online download statistics by month:

Online download statistics by month: December 2019 to February 2026

AbstractFullPdf
Dec 2019110
Jan 202014142
Feb 202037378
Mar 202048485
Apr 202034344
May 202048486
Jun 202035353
Jul 202033333
Aug 202036349
Sep 202060604
Oct 2020393912
Nov 2020404214
Dec 2020484819
Jan 2021383810
Feb 2021333412
Mar 202132324
Apr 2021616125
May 2021292914
Jun 2021242411
Jul 2021262611
Aug 2021343417
Sep 2021333321
Oct 2021303030
Nov 2021282830
Dec 2021212116
Jan 2022373815
Feb 2022575810
Mar 2022515217
Apr 2022525719
May 2022495632
Jun 2022424515
Jul 202220209
Aug 202227278
Sep 2022656755
Oct 2022272711
Nov 2022252721
Dec 202226266
Jan 202321219
Feb 202324248
Mar 2023323320
Apr 2023131311
May 2023404026
Jun 2023353511
Jul 2023343414
Aug 2023252513
Sep 2023293013
Oct 2023404217
Nov 2023181814
Dec 202325268
Jan 2024404010
Feb 2024454526
Mar 2024535425
Apr 2024353616
May 2024323213
Jun 2024434320
Jul 2024595913
Aug 202432348
Sep 2024252513
Oct 2024767521
Nov 2024484920
Dec 2024565616
Jan 2025383824
Feb 2025404032
Mar 2025586022
Apr 2025656514
May 2025575725
Jun 2025303113
Jul 2025110
Aug 2025110
Sep 2025110
Oct 2025110
Nov 2025110
Jan 2026110
Feb 2026110
Total251525501003